LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) is investigating potential claims on behalf of investors of Amgen Inc. (“Amgen” or the “Company”) (NASDAQ: AMGN) concerning the Company and its officers’ possible violations of federal securities laws.
GPM represents investors in securities class actions, seeking to recoup damages caused by corporate fraud and wrongdoing.
On May 22, 2017, Amgen disclosed that approval for Evenity, the Company’s osteoporosis medicine, will be delayed due to heart safety concerns. According to Amgen, a higher percentage of patients who took Evenity experienced cardiovascular side effects after a year, than those who took an older, but approved medicine.
On this news, shares of Amgen fell over 2% on May 22, 2017.
If you purchased Amgen securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to email@example.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.